TMS Past Earnings Performance
Past criteria checks 0/6
TMS's earnings have been declining at an average annual rate of -35.4%, while the Biotechs industry saw earnings growing at 11.1% annually.
Key information
-35.4%
Earnings growth rate
51.4%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | n/a |
| Return on equity | -36.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Aug 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How TMS makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 24 | 0 | -1,095 | 319 | 708 |
| 31 May 24 | 0 | -1,059 | 307 | 685 |
| 29 Feb 24 | 0 | -960 | 313 | 607 |
| 30 Nov 23 | 0 | -671 | 197 | 459 |
| 31 Aug 23 | 0 | -734 | 221 | 359 |
| 31 May 23 | 0 | -774 | 222 | 298 |
| 28 Feb 23 | 0 | -860 | 205 | 297 |
| 28 Feb 22 | 1,946 | 1,076 | 506 | 304 |
Quality Earnings: 4891 is currently unprofitable.
Growing Profit Margin: 4891 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4891 is unprofitable, and losses have increased over the past 5 years at a rate of 35.4% per year.
Accelerating Growth: Unable to compare 4891's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4891 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 4891 has a negative Return on Equity (-36.65%), as it is currently unprofitable.